You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020295020
Dec 20202407
Jan 20214408
Feb 202161012
Mar 2021125018
Apr 2021100012
May 202118016
Jun 2021009
Jul 20210010
Aug 2021005
Sep 2021007
Oct 202142048
Nov 202154032
Dec 20214005
Jan 202274021
Feb 202254012
Mar 202286017
Apr 202282012
May 20227204
Jun 202211508
Jul 202213008
Aug 2022135016
Sep 20224406
Oct 20224202
Nov 202275014
Dec 202274015
Jan 202392014
Feb 20237206
Mar 202313406
Apr 20235606
May 2023104013
Jun 20234403
Jul 20234005
Aug 20233605
Sep 20236003
Oct 20235007
Nov 20235604
Dec 20234002
Jan 20243605
Feb 20243604
Mar 20244808
Apr 202468011
May 20244805
Jun 20242803
Jul 20244404
Aug 20245205
Sep 20248202
Oct 2024128014
Nov 20249607
Dec 20244408
Jan 202568011
Feb 20251205
Mar 2025001
Apr 2025008
May 20250010
Jun 2025005
Total33600534